Infant Bacterial Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Infant Bacterial Therapeutics is Staffan Stromberg, benoemd in Jan2013, heeft een ambtstermijn van 11.83 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 5.33M, bestaande uit 57.9% salaris en 42.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.79% van de aandelen van het bedrijf, ter waarde SEK 4.11M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.5 jaar en 7.5 jaar.

Belangrijke informatie

Staffan Stromberg

Algemeen directeur

SEK 5.3m

Totale compensatie

Percentage CEO-salaris	57.9%
Dienstverband CEO	11.8yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	7.5yrs

Recente managementupdates

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02

Recent updates

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 02

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

May 02

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Apr 03

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Sep 16

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

May 11

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Sep 23

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Apr 07

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Dec 15

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Aug 25

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

May 06

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Feb 07

Analyse CEO-vergoeding

Hoe is Staffan Stromberg's beloning veranderd ten opzichte van Infant Bacterial Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-SEK 144m
Jun 30 2024	n/a	n/a	-SEK 142m
Mar 31 2024	n/a	n/a	-SEK 128m
Dec 31 2023	SEK 5m	SEK 3m	-SEK 123m
Sep 30 2023	n/a	n/a	-SEK 122m
Jun 30 2023	n/a	n/a	-SEK 99m
Mar 31 2023	n/a	n/a	-SEK 69m
Dec 31 2022	SEK 6m	SEK 3m	-SEK 65m
Sep 30 2022	n/a	n/a	-SEK 42m
Jun 30 2022	n/a	n/a	-SEK 34m
Mar 31 2022	n/a	n/a	-SEK 65m
Dec 31 2021	SEK 5m	SEK 3m	-SEK 45m
Sep 30 2021	n/a	n/a	-SEK 55m
Jun 30 2021	n/a	n/a	-SEK 74m
Mar 31 2021	n/a	n/a	-SEK 73m
Dec 31 2020	SEK 4m	SEK 2m	-SEK 72m
Sep 30 2020	n/a	n/a	-SEK 73m
Jun 30 2020	n/a	n/a	-SEK 65m
Mar 31 2020	n/a	n/a	-SEK 44m
Dec 31 2019	SEK 3m	SEK 2m	-SEK 46m
Sep 30 2019	n/a	n/a	-SEK 43m
Jun 30 2019	n/a	n/a	-SEK 40m
Mar 31 2019	n/a	n/a	-SEK 32m
Dec 31 2018	SEK 3m	SEK 2m	-SEK 41m
Sep 30 2018	n/a	n/a	-SEK 26m
Jun 30 2018	n/a	n/a	-SEK 22m
Mar 31 2018	n/a	n/a	-SEK 37m
Dec 31 2017	SEK 3m	SEK 1m	-SEK 36m

Compensatie versus markt: De totale vergoeding ($USD 488.37K ) Staffan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 236.58K ).

Compensatie versus inkomsten: De vergoeding van Staffan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Staffan Stromberg (57 yo)

11.8yrs

Tenure

SEK 5,327,000

Compensatie

Mr. Staffan Stromberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Stromberg served as Director at Genetic Analysis AS since October 28, 2020 u...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Staffan Stromberg	Chief Executive Officer	11.8yrs	SEK 5.33m	0.79% SEK 4.1m
Maria Ekdahl	Chief Financial Officer	2.2yrs	geen gegevens	0.035% SEK 180.7k
Anders Kronström	Chief Operating Officer	6.8yrs	SEK 500.00k	0.083% SEK 429.8k
Thomas Schnitzer	Chief Scientific Officer	less than a year	geen gegevens	geen gegevens
Sanjiv Sharma	Head of Medical Affairs	less than a year	geen gegevens	geen gegevens
Jonas Rastad	Chief Medical Officer	less than a year	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IBT B wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Rothschild	Chairman	13.8yrs	SEK 727.00k	geen gegevens
Margareta Hagman	Independent Director	9.2yrs	SEK 153.00k	0.039% SEK 202.9k
Eva Idén	Independent Director	7.5yrs	SEK 153.00k	0.0042% SEK 21.5k
Kristina Nygren	Independent Director	6.5yrs	SEK 153.00k	0.00074% SEK 3.8k
Anthon Jahreskog	Independent Director	7.5yrs	SEK 193.00k	0.18% SEK 932.0k

7.5yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IBT B wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.5 jaar).

Infant Bacterial Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2025

Independent Director recently bought kr350k worth of stock

Independent Director recently bought kr222k worth of stock

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr90k worth of stock

Recent updates

Infant Bacterial Therapeutics AB (publ) to Report Q3, 2025 Results on Nov 13, 2025

Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2025

Independent Director recently bought kr350k worth of stock

New minor risk - Market cap size

Infant Bacterial Therapeutics Announces Results of Phase III Study Shows No Significant Effects on the Primary Endpoints

New minor risk - Share price stability

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Independent Director recently bought kr222k worth of stock

Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment

Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans

Infant Bacterial Therapeutics AB (publ) to Report Nine Months, 2024 Results on Nov 14, 2024

New minor risk - Market cap size

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr90k worth of stock

Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2024

Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation

Infant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2023 Results on Feb 08, 2024

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Independent Director recently bought kr86k worth of stock

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ) Publishes Clinical Findings in British Journal of Gastroenterology

Infant Bacterial Therapeutics AB Secures Platform for Pharma Grade Probiotic to Prevent Antibiotic Resistant Hospital Acquired Infections

Insufficient new directors

Infant Bacterial Therapeutics AB (publ) Announces Nomination Committee Appointments

FDA Approves Infant Bacterial Therapeutics' Request for a New Orphan Drug Designation

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Infant Bacterial Therapeutics AB (publ) to Report Q2, 2023 Results on Aug 25, 2023

Infant Bacterial Therapeutics AB (publ) Appoints Maria Ekdahl as Chief Financial Officer, Effective September 19, 2022

Insufficient new directors

Infant Bacterial Therapeutics AB (Publ) Announces Retirement of Michael Owens as CFO

We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely

Independent Director recently bought kr59k worth of stock

Infant Bacterial Therapeutics Announces the Connection Study Continues After Pre-Scheduled Data Monitoring Committee Review

Infant Bacterial Therapeutics AB Announces New Patent Protection Granted in Australia

Infant Bacterial Therapeutics Announces New Patent Protection Approvals in Brazil and in Hong Kong

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Infant Bacterial Therapeutics AB (publ) Announces After Safety Review the Connection Study Is Now Again Open to Recruit the Smallest Infants

Infant Bacterial Therapeutics Announces the Mexican Patent Office Grants New Patent

Infant Bacterial Therapeutics AB (Publ) Announces Recruitment of the Smallest Infants in the Connection Study Paused

We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth

Interim Chief Financial Officer Michael Owens has left the company

Independent Director recently bought kr113k worth of stock

Independent Director recently bought kr113k worth of stock

Director recently bought kr382k worth of stock

We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate

Chief Operating Officer recently bought kr350k worth of stock

Infant Bacterial Therapeutics Announces That the Recruitment to the First Stage of the Phase III Connection Study Is Completed - an Update About the Clinical Development of IBP-9414

Infant Bacterial Therapeutics Announces Grant of New Patent in Japan

Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)

Insider recently bought kr118k worth of stock

New 90-day low: kr106

New 90-day low: kr123

New 90-day low: kr131

Infant Bacterial Therapeutics AB (publ) to Report Q1, 2021 Results on May 04, 2021

New 90-day high - kr119

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd